Adding lixisenatide to metformin and insulin glargine significantly reduced glycated hemoglobin levels and improved post-prandial glucose in patients with type 2 diabetes....
Advertisement
In the randomized, double-blind, placebo-controlled GetGoal Duo 1 study, patients uncontrolled on oral medication -- mainly metformin -- received either lixisenatide once-daily or placebo while insulin glargine and metformin were continued. Patients had already decreased their HbA1c -- the primary efficacy endpoint -- on average from 8.60% to 7.60% during a 12-week run-in period with insulin glargine.
After a 24-week randomization phase, those on lixisenatide had further significantly decreased HbA1c compared with placebo (P<0.0001) to a mean value of 6.96%, with a significantly higher percentage of patients achieving target HbA1c less than 7.0% with lixisenatide compared with placebo (56.3% versus 38.5%, respectively, P=0.0001), according to Sanofi's press release.
Sanofi has submitted a request to the European Medicines Agency for regulatory approval and expects to submit a similar request to the FDA toward the end of 2012.
The full study results from GetGoal Duo 1 will be presented at a future medical congress, the company said.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.
Entries (RSS News)
